Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
European Journal of Nuclear Medicine and Molecular Imaging|March 12, 2025
A cost-effectiveness study of PSMA-PET/CT for the detection of clinically significant prostate cancerBastiaan M Privé, Tim M Govers, Bas Israël, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 17, 2019
Accuracy of 18F-FDG PET/CT in Predicting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal CancerMaria J Valkema, Bo Jan Noordman, Bas P L Wijnhoven, et al.Radiology|May 21, 2024
Multiparametric MRI and 18F-PSMA-1007 PET/CT for the Detection of Clinically Significant Prostate CancerBastiaan M Privé, Bas Israël, Marcel J R Janssen, et al.Frontiers in Nuclear Medicine|October 2, 2024
An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate CancerBastiaan M Privé, Constantijn H J Muselaers, Inge M van Oort, et al.Prostate Cancer and Prostatic Diseases|July 8, 2022
Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapyMaarten J van der Doelen, Irma M Oving, Dirk N J Wyndaele, et al.Prostate Cancer and Prostatic Diseases|July 13, 2021
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancerBastiaan M Privé, Peter H J Slootbeek, Babette I Laarhuis, et al.Cancers|January 8, 2023
PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective StudyAmina Banda, Bastiaan M Privé, Youssra Allach, et al.Nature Communications|October 18, 2022
Reprogramming of myeloid cells and their progenitors in patients with non-medullary thyroid carcinomaKatrin Rabold, Martijn Zoodsma, Inge Grondman, et al.BMC Cancer|September 15, 2020
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trialBastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.The Lancet. Oncology|April 2, 2026
[177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 studyBastiaan M Privé, Walter Noordzij, Constantijn H J Muselaers, et al.Pageof 5